Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BPK-29 is a specific ligand that disrupts the atypical orphan nuclear receptor NR0B1-protein interactions by covalently modifying C274. It impairs the anchorage-independent growth of KEAP1-mutant cancer cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | BPK-29 is a specific ligand that disrupts the atypical orphan nuclear receptor NR0B1-protein interactions by covalently modifying C274. It impairs the anchorage-independent growth of KEAP1-mutant cancer cells. |
In vitro | BPK-29 effectively targets NR0B1, demonstrating considerable proteomic selectivity within KEAP1-mutant Non-Small Cell Lung Cancers (NSCLCs)[1]. |
Molecular Weight | 470 |
Formula | C26H32ClN3O3 |
CAS No. | 2143467-62-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BPK-29 2143467-62-1 Others BPK 29 BPK29 inhibitor inhibit